---
figid: PMC11216096__fonc-14-1410513-g002
figtitle: 'Wnt signaling in gastric cancer: current progress and future prospects'
organisms:
- NA
organisms_ner:
- Danio rerio
- Homo sapiens
pmcid: PMC11216096
filename: fonc-14-1410513-g002.jpg
figlink: /pmc/articles/PMC11216096/figure/f2/
number: F2
caption: The roles of Wnt pathway members and Wnt-targeted agents in gastric cancer.
  Wnt ligands and FZD receptors are altered in gastric cancer. The background colors
  of the following various Wnt-targeted agents are shown in light blue boxes. DKKs
  and PORCNi are Wnt ligand antagonists, pAb5a-5 targets and inhibits WNT5A, Ad5/35-DKK1
  delivers DKK1, miR-132–3p and miR-140–5p inhibit WNT1, miR-491–5p inhibits Wnt3a,
  and miR-876–5p and mi-26a-5p inhibit WNT5A. OMP-18R5 targets and inhibits the FZD
  receptor, Fz7–21 inhibits FZD7. OMP-54F28 inhibits FZD8. CCT5 inhibits β-catenin
  adhesion to E-cadherin, salinomycin inhibits LRP5/6, and OMP131-R10 inhibits the
  Znrf3-/Rnf43-scavenging effect of RSPO. M435–1279 inhibits UBT2T-induces β-catenin
  accumulation in the nucleus. XAV939 promotes β-catenin degradation. iCRT3/5 and
  LF3 inhibit the interaction of β-catenin and TCF4. 2,4-DAQ inhibits LEF1, and E7386
  inhibits the interaction between β-catenin and CBP.
papertitle: 'Wnt signaling in gastric cancer: current progress and future prospects.'
reftext: Ruyue Han, et al. Front Oncol. 2024;14:1410513.
year: '2024'
doi: 10.3389/fonc.2024.1410513
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media S.A.
keywords: gastric cancer | Wnt | EMT | tumor microenvironment | molecular agents
automl_pathway: 0.9199068
figid_alias: PMC11216096__F2
figtype: Figure
redirect_from: /figures/PMC11216096__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11216096__fonc-14-1410513-g002.html
  '@type': Dataset
  description: The roles of Wnt pathway members and Wnt-targeted agents in gastric
    cancer. Wnt ligands and FZD receptors are altered in gastric cancer. The background
    colors of the following various Wnt-targeted agents are shown in light blue boxes.
    DKKs and PORCNi are Wnt ligand antagonists, pAb5a-5 targets and inhibits WNT5A,
    Ad5/35-DKK1 delivers DKK1, miR-132–3p and miR-140–5p inhibit WNT1, miR-491–5p
    inhibits Wnt3a, and miR-876–5p and mi-26a-5p inhibit WNT5A. OMP-18R5 targets and
    inhibits the FZD receptor, Fz7–21 inhibits FZD7. OMP-54F28 inhibits FZD8. CCT5
    inhibits β-catenin adhesion to E-cadherin, salinomycin inhibits LRP5/6, and OMP131-R10
    inhibits the Znrf3-/Rnf43-scavenging effect of RSPO. M435–1279 inhibits UBT2T-induces
    β-catenin accumulation in the nucleus. XAV939 promotes β-catenin degradation.
    iCRT3/5 and LF3 inhibit the interaction of β-catenin and TCF4. 2,4-DAQ inhibits
    LEF1, and E7386 inhibits the interaction between β-catenin and CBP.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - wnt3
  - wnt3a
  - wnt2ba
  - wnt2
  - wnt1
  - wnt10b
  - wnt4
  - wnt5a
  - mir140
  - fzd4
  - fzd3a
  - fzd2
  - fzd10
  - fzd6
  - fzd5
  - cdh1
  - si:busm1-180o5.1
  - si:busm1-180o5.2
  - lrp5
  - lrp6
  - ctnnb1
  - ror1
  - ror2
  - rnf43
  - apc
  - tcf4
  - tcf7l2
  - WNT3
  - WNT2B
  - WNT2
  - WNT1
  - WNT10B
  - WNT4
  - WNT5A
  - MIR140
  - MIR876
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - RNU6-664P
  - CDH1
  - FZR1
  - RSPO1
  - LRP5
  - LRP6
  - P2RY6
  - CTNNB1
  - ROR1
  - RORA
  - ROR2
  - RNF43
  - AXIN1
  - AXIN2
  - APC
  - PROC
  - CSNK1A1
  - TCF4
  - TCF7L2
  - EP300
---
